{"id":948834,"date":"2026-04-02T17:12:29","date_gmt":"2026-04-02T21:12:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/"},"modified":"2026-04-02T17:12:29","modified_gmt":"2026-04-02T21:12:29","slug":"fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/","title":{"rendered":"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2026, the Company granted restricted stock units (RSUs) representing 7,260 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company\u2019s Board of Directors and granted under the Company\u2019s Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.<\/p>\n

\n About Fate Therapeutics, Inc.<\/strong>
\n
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company\u2019s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com<\/a>.<\/p>\n

\n Contact:<\/strong>
\n
Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2026, the Company granted restricted stock units (RSUs) representing 7,260 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company\u2019s Board of Directors and granted under the Company\u2019s Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of … <\/p>\n

Continue reading “Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-948834","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2026, the Company granted restricted stock units (RSUs) representing 7,260 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company\u2019s Board of Directors and granted under the Company\u2019s Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of … Continue reading "Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-02T21:12:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzY0OSM3NTE4MjY5IzIwMDQyMDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-04-02T21:12:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\\\/\"},\"wordCount\":274,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzY0OSM3NTE4MjY5IzIwMDQyMDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\\\/\",\"name\":\"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzY0OSM3NTE4MjY5IzIwMDQyMDE=\",\"datePublished\":\"2026-04-02T21:12:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzY0OSM3NTE4MjY5IzIwMDQyMDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MzY0OSM3NTE4MjY5IzIwMDQyMDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/","og_locale":"en_US","og_type":"article","og_title":"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2026, the Company granted restricted stock units (RSUs) representing 7,260 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company\u2019s Board of Directors and granted under the Company\u2019s Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of … Continue reading \"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-02T21:12:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzY0OSM3NTE4MjY5IzIwMDQyMDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-04-02T21:12:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/"},"wordCount":274,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzY0OSM3NTE4MjY5IzIwMDQyMDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/","name":"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzY0OSM3NTE4MjY5IzIwMDQyMDE=","datePublished":"2026-04-02T21:12:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzY0OSM3NTE4MjY5IzIwMDQyMDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MzY0OSM3NTE4MjY5IzIwMDQyMDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fate-therapeutics-reports-new-employee-inducement-award-under-nasdaq-listing-rule-5635c4-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/948834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=948834"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/948834\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=948834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=948834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=948834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}